Why the study?
The relationship between the clinical efficacy of vericiguat and baseline renal function as well as subsequent changes in renal function in worsening HFrEF remained to be evaluated.
Does vericiguat reduce cardiovascular death or heart failure hospitalization in patients with worsening HFrEF irrespective of baseline renal function or worsening renal function?
Does vericiguat reduce cardiovascular death or heart failure hospitalization in patients with worsening HFrEF irrespective of baseline renal function or worsening renal function?
Vericiguat maintains its efficacy in reducing cardiovascular death or heart failure hospitalization in patients with worsening HFrEF regardless of baseline renal function or subsequent worsening renal function.
No takes yet. Share an insight, caveat, or question.
Supports vericiguat consideration across eGFR strata in worsening HFrEF; extends prior data observationally but remains hypothesis-generating.
Voors et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: